For much of women's health, hormones have been considered primarily in terms of where they are produced, how much is circulating and what happens when concentrations rise or fall. Oestrogen is discussed in relation to the menstrual cycle, fertility, pregnancy, perimenopause and menopause, as well as bone, cardiovascular, metabolic and brain health. What receives less attention is what happens after oestrogen has circulated through the body and reached the liver, and the role that intestinal microorganisms may play in determining what happens next. This is where the estrobolome enters the picture.
The term describes the collection of gut microbial genes capable of metabolising oestrogens. Rather than representing one particular bacterial species, the estrobolome is principally about function: the capacity of microorganisms within the intestine to modify oestrogen and potentially influence its availability to the host. This is an important distinction because microbiome science is increasingly moving away from simply asking which bacteria are present and towards the more interesting question of what those microorganisms are actually doing.
What happens to oestrogen in the gut?
Oestrogens, including oestradiol, oestrone and oestriol, circulate through the body before undergoing metabolism, much of which occurs in the liver. During this process, oestrogens can be conjugated, making them more water-soluble and facilitating their elimination through urine or bile. Those entering bile eventually reach the intestine. This might sound like the end of their journey, but it is not necessarily so.
Certain intestinal microorganisms produce enzymes capable of deconjugating these oestrogens. Once deconjugated, some may become available for reabsorption across the intestinal wall and return to the circulation through enterohepatic recycling. One of the enzymes receiving particular attention is β-glucuronidase, which can remove glucuronic-acid groups from conjugated oestrogens and potentially allow oestrogen to be reactivated rather than excreted.
Even this may be only part of the picture. A 2026 review drew attention to bacterial sulfatases, enzymes capable of converting sulfated oestrogens into active forms. This is potentially important because oestrogen sulfates represent a substantial circulating reservoir and can enter the intestine through bile. The authors argue that the contribution of microbial sulfatases to oestrogen reactivation deserves considerably more investigation.
The estrobolome therefore cannot be reduced to one enzyme. Current research is examining a wider microbial network involving β-glucuronidases, sulfatases, hydroxysteroid dehydrogenases and other pathways through which microorganisms may participate in steroid metabolism.
Oestrogen and the microbiome: a two-way relationship
It would be convenient if this relationship operated in one direction: gut bacteria affect oestrogen. Human biology is rarely that obliging. Oestrogen itself appears capable of influencing intestinal physiology and microbial ecology. Hormonal changes across a woman's life may therefore affect the microbial environment, while microbial activity may influence the metabolism of hormones.
Menopause provides an obvious natural model in which to investigate this relationship because ovarian oestradiol production falls substantially. However, one of the most useful developments in recent research has been a move away from the simplistic idea that menopause automatically produces a universally poorer microbiome.
A 2026 systematic review and meta-analysis examined women with lower-oestrogen states, including postmenopause and premature ovarian insufficiency, compared with premenopausal controls. Seven studies were included, comprising 1,222 postmenopausal women, 45 women with premature ovarian insufficiency and 463 controls. The researchers found no significant overall differences in alpha diversity or in the abundance of the major bacterial phyla examined. Heterogeneity between studies was substantial.
This matters because it challenges the increasingly common suggestion that there is a single ideal female microbiome that deteriorates as oestrogen falls. The reality is likely to be considerably more interesting. Microbial function may matter as much as microbial composition.
A separate 2026 review examining estradiol loss, the estrobolome and midlife symptoms concluded that the microbiome may interact with endocrine pathways during menopause, while emphasising that much of the human evidence remains observational and that causal relationships still need to be established.
The estrobolome is not an oestrogen dial
There is a tendency within the wellness industry to take emerging physiology and turn it into an instruction: increase one organism, suppress another enzyme and “balance your hormones”. The estrobolome does not work like that.
Oestrogen exposure is influenced by ovarian function, age, adipose tissue, liver metabolism, genetics, medication, diet and numerous other factors alongside microbial activity. β-glucuronidase itself should not simply be labelled “bad”; deconjugation forms part of normal physiology. This distinction becomes particularly important when considering oestrogen-sensitive conditions.
Research is examining estrobolome function in relation to breast and endometrial cancer, PCOS and endometriosis. A 2025 review of oestrogen-metabolising pathways of the gut microbiome in breast cancer identified plausible microbial targets but concluded that precise mechanisms remain incompletely characterised. A further 2026 review describes microbial enzymes as potential contributors to enterohepatic oestrogen recycling, inflammation, immune responses and hormone bioavailability, while stressing that human evidence remains largely associative.
This does not diminish the importance of the estrobolome. It simply places the science where it belongs: an important and developing component of women's health rather than a single explanation for hormone-dependent disease.
Diet and the estrobolome
Nutrition enters this relationship through several routes. Dietary fibre provides substrates for microbial fermentation and helps shape microbial ecology and metabolic activity. Plant foods also provide polyphenols and phytoestrogens, some of which undergo further transformation by intestinal microorganisms.
Soy provides a useful example. The isoflavone daidzein can be metabolised by certain gut microorganisms into equol, a metabolite with different biological activity from its dietary precursor. However, not everybody possesses the microbial capacity to produce equol. Two women can therefore consume the same food and potentially experience different microbial metabolism.
This illustrates why nutritional microbiome science is moving beyond lists of supposedly “good” and “bad” bacteria. Food supplies substrates, microorganisms transform those substrates, microbial products interact with the host, and the host environment influences which microbial activities occur.
A dietary pattern containing a broad range of vegetables, fruit, legumes, wholegrains, nuts, seeds, herbs and spices therefore makes biological sense because it supplies a diverse range of fibres and phytochemicals to the intestinal microbial ecosystem. This is a more defensible nutritional position than suggesting that a particular food can “detox excess oestrogen”.
There is no established estrobolome diet. There is, however, increasingly good reason to consider diet, microbial function and hormonal physiology as interconnected rather than independent systems.
Where postbiotics become interesting
The developing science of the estrobolome is part of a much wider change in our understanding of the microbiome. The question is no longer simply which microorganisms are present? Researchers also want to know what microorganisms produce, which components interact with human cells and what biological signals pass between microorganisms and the host. This is where postbiotic science becomes relevant.
Postbiotics are preparations of inanimate microorganisms and/or their components that confer a demonstrated health benefit. Unlike probiotics, they do not depend upon live microorganisms remaining viable during manufacture, storage and their journey through the gastrointestinal tract. Instead, they allow microbial cells and components to interact with host physiology without relying upon the administration of viable organisms.
This distinction is particularly interesting when we consider the estrobolome. If microbial function matters, supporting the relationship between the microbiome and the host need not be confined to changing the number or identity of living bacteria.
Postbiotic research is investigating effects involving intestinal barrier integrity, immune regulation, inflammatory signalling and metabolism. These are biological systems that interact with hormonal change, metabolic health and healthy ageing.
A randomised, double-blind, placebo-controlled trial in healthy women aged 40-55 investigated supplementation with a postbiotic preparation derived from Bifidobacterium breve. The study assessed inflammatory markers and endocrine measures over 12 weeks and reported changes in inflammatory status and markers of endocrine function in the supplemented group. The trial was small - 30 women - and involved one specific preparation, so its findings cannot automatically be generalised to other postbiotics. Nevertheless, it is important because it moves the discussion beyond theoretical mechanisms: postbiotics have entered randomised controlled human research in women's health.
The clinical literature is continuing to develop. A 2026 randomised, double-blind controlled trial investigated a Lactobacillus crispatus-derived postbiotic in women with vulvar lichen sclerosus, providing another example of defined postbiotic preparations being investigated directly within women's health rather than solely in general gastrointestinal research. Again, this is a condition-specific preparation and should not be extrapolated to unrelated women's-health outcomes, but it demonstrates the breadth into which postbiotic research is moving.
We cannot currently say that a particular postbiotic will predictably modify oestrogen recycling through the estrobolome or “balance” a woman's hormones. What we can say is that postbiotics are being investigated in women, that human randomised trials exist, and that the biological systems influenced by postbiotic preparations overlap with several of the pathways now being investigated in women's microbiome and hormonal health.
Women's health is more than hormone levels
Perhaps the most useful contribution of estrobolome research is that it changes the way we think about hormones. Oestrogen does not exist in isolation from the liver, intestine, diet, adipose tissue, immune system or microbial environment. The concentration measured in the circulation represents only one part of a much larger metabolic process.
The microbiome adds another participant to that process and the 2026 literature gives us good reason both to be interested and to resist oversimplification. We cannot yet identify an ideal “female microbiome”, nor should we assume that lower oestrogen automatically produces one particular microbial signature. At the same time, we now know that intestinal microorganisms possess enzymes capable of participating in oestrogen metabolism and enterohepatic recycling, and that the relationship between oestrogen and the microbiome appears to operate in both directions.
Postbiotic science adds another dimension. Rather than focusing solely on introducing living microorganisms, it asks what happens when defined microbial cells and components interact with human physiology. Human RCTs in women are beginning to explore that question, while the wider evidence around barrier biology, immune signalling, inflammation and metabolism provides further biological context.
For decades, women's hormones have often been discussed as though the endocrine system operates within its own boundaries. The estrobolome challenges that view. The gut does far more than digest our food. Its microorganisms interact with compounds made by our own bodies, transform components of our diet and participate in signalling pathways reaching far beyond the intestine.
As women's microbiome research develops, postbiotics give us another way of exploring - and potentially supporting - that relationship between microorganisms and the female body.
References
1. Saravinovska K, et al. The impact of estrogen status on the gut microbiome: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2026;17:1780806. 2. Estrobolome: Is there a missing link? 2026. PMID: 41707838. 3. Mou E, et al. Beyond estrobolome 1.0: unraveling endocrine-microbiome axis as a driver and therapeutic target in hormone-driven cancers. NPJ Biofilms Microbiomes. 2026. 4. Palacios S, et al. Estradiol loss, the “estrobolome,” and midlife symptoms: what the gut microbiome adds to menopause care. Menopause. 2026. 5. Larnder AH, Manges AR, Murphy RA. The estrobolome: Estrogen-metabolizing pathways of the gut microbiome and their relation to breast cancer. Int J Cancer. 2025;157(4):599-613. 6. El-Sehrawy AAMA, et al. Estrobolome and the endocrine-microbiome axis in breast and endometrial carcinogenesis. Crit Rev Oncol Hematol. 2026;225:105471. 7. From Gut to Hormones: Unraveling the Role of Gut Microbiota in (Phyto)Estrogen Modulation in Health and Disease. Mol Nutr Food Res. 2024. 8. Motei DE, et al. Supplementation with postbiotic from Bifidobacterium breve BB091109 improves inflammatory status and endocrine function in healthy females: a randomized, double-blind, placebo-controlled, parallel-groups study. Front Microbiol. 2023. 9. Liao H, et al. Postbiotics originated from Lactobacillus crispatus NCU-31 improves vulvar lichen sclerosus: a randomized, double-blind controlled trial. BMC Microbiol. 2026;26:188.
Kate Arnold, Nutrition Consultant to The Postbiotic Company
This article is intended for educational and scientific information only. It does not constitute medical advice and should not be used to diagnose, prevent or treat any medical condition. References to postbiotic research relate to the specific preparations and populations studied and should not be assumed to apply to all postbiotic products.
